OA12386A - Pharmaceutical composition and method for treatinghypogonadism. - Google Patents

Pharmaceutical composition and method for treatinghypogonadism. Download PDF

Info

Publication number: OA12386A
Authority: OA; OAPI
Prior art keywords: day; testosterone; androgel; gel; patch
Prior art date: 2000-08-30

Application number

OA1200300069A

Other languages

English (en)

Inventor

Robert E Dudley

George S Kottayil

Oliver Palatchi

Original Assignee

Lab Besins Iscovesco

Unimed Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-30

Filing date

2001-08-29

Publication date

2006-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24614189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-08-29 Application filed by Lab Besins Iscovesco, Unimed Pharmaceuticals Inc filed Critical Lab Besins Iscovesco

2006-04-17 Publication of OA12386A publication Critical patent/OA12386A/en

Links

238000000034 method Methods 0.000 title claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
239000000203 mixture Substances 0.000 claims abstract description 38
206010058359 Hypogonadism Diseases 0.000 claims abstract description 24
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 911
229960003604 testosterone Drugs 0.000 claims description 342
238000011282 treatment Methods 0.000 claims description 136
230000001965 increasing effect Effects 0.000 claims description 33
230000007423 decrease Effects 0.000 claims description 24
230000036651 mood Effects 0.000 claims description 23
210000003205 muscle Anatomy 0.000 claims description 18
206010040880 Skin irritation Diseases 0.000 claims description 13
210000000988 bone and bone Anatomy 0.000 claims description 13
-1 polyethylene Polymers 0.000 claims description 13
231100000475 skin irritation Toxicity 0.000 claims description 13
230000036556 skin irritation Effects 0.000 claims description 13
235000014113 dietary fatty acids Nutrition 0.000 claims description 12
229930195729 fatty acid Natural products 0.000 claims description 12
239000000194 fatty acid Substances 0.000 claims description 12
239000003623 enhancer Substances 0.000 claims description 9
230000035936 sexual power Effects 0.000 claims description 8
239000004698 Polyethylene Substances 0.000 claims description 7
150000004665 fatty acids Chemical class 0.000 claims description 7
229920000573 polyethylene Polymers 0.000 claims description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
239000011888 foil Substances 0.000 claims description 5
229920002125 Sokalan® Polymers 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
206010024421 Libido increased Diseases 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229940074928 isopropyl myristate Drugs 0.000 claims 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
239000003098 androgen Substances 0.000 abstract description 14
239000003263 anabolic agent Substances 0.000 abstract 1
230000001548 androgenic effect Effects 0.000 abstract 1
239000003961 penetration enhancing agent Substances 0.000 abstract 1
229940062331 androgel Drugs 0.000 description 164
239000000499 gel Substances 0.000 description 122
238000011221 initial treatment Methods 0.000 description 48
238000003556 assay Methods 0.000 description 39
230000008859 change Effects 0.000 description 29
210000003491 skin Anatomy 0.000 description 26
239000011575 calcium Substances 0.000 description 19
230000003247 decreasing effect Effects 0.000 description 19
239000003814 drug Substances 0.000 description 16
229940088597 hormone Drugs 0.000 description 16
239000005556 hormone Substances 0.000 description 16
239000007943 implant Substances 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 14
102100030758 Sex hormone-binding globulin Human genes 0.000 description 14
229940059312 androderm Drugs 0.000 description 13
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 13
229940079593 drug Drugs 0.000 description 13
230000001568 sexual effect Effects 0.000 description 13
238000012360 testing method Methods 0.000 description 13
229940090044 injection Drugs 0.000 description 12
229910052791 calcium Inorganic materials 0.000 description 11
230000004044 response Effects 0.000 description 11
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
102000004067 Osteocalcin Human genes 0.000 description 10
108090000573 Osteocalcin Proteins 0.000 description 10
210000002700 urine Anatomy 0.000 description 10
230000002829 reductive effect Effects 0.000 description 9
235000012237 sodium aluminium phosphate Nutrition 0.000 description 9
IQQWMJSNEUUJAY-UHFFFAOYSA-D trialuminum;sodium;dihydrogen phosphate;hydrogen phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Al+3].[Al+3].[Al+3].OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP([O-])([O-])=O.OP([O-])([O-])=O IQQWMJSNEUUJAY-UHFFFAOYSA-D 0.000 description 9
206010015150 Erythema Diseases 0.000 description 8
206010059594 Secondary hypogonadism Diseases 0.000 description 8
238000013103 analytical ultracentrifugation Methods 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 8
231100000321 erythema Toxicity 0.000 description 8
201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 8
230000006872 improvement Effects 0.000 description 8
210000002414 leg Anatomy 0.000 description 8
230000035941 sexual motivation Effects 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
206010052649 Primary hypogonadism Diseases 0.000 description 7
238000009165 androgen replacement therapy Methods 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000003127 radioimmunoassay Methods 0.000 description 7
230000002485 urinary effect Effects 0.000 description 7
102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 6
108010050808 Procollagen Proteins 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000037361 pathway Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
206010040914 Skin reaction Diseases 0.000 description 5
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000035483 skin reaction Effects 0.000 description 5
231100000430 skin reaction Toxicity 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
108010010234 HDL Lipoproteins Proteins 0.000 description 4
102000015779 HDL Lipoproteins Human genes 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
210000001015 abdomen Anatomy 0.000 description 4
230000002411 adverse Effects 0.000 description 4
230000032683 aging Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000012421 spiking Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
108010082126 Alanine transaminase Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000006771 Gonadotropins Human genes 0.000 description 3
108010086677 Gonadotropins Proteins 0.000 description 3
206010022998 Irritability Diseases 0.000 description 3
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000004820 blood count Methods 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 3
229960001751 fluoxymesterone Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000002622 gonadotropin Substances 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000011164 ossification Effects 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000035946 sexual desire Effects 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
CBMYJHIOYJEBSB-KHOSGYARSA-N 5alpha-androstane-3alpha,17beta-diol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-KHOSGYARSA-N 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
201000007493 Kallmann syndrome Diseases 0.000 description 2
208000017924 Klinefelter Syndrome Diseases 0.000 description 2
206010029216 Nervousness Diseases 0.000 description 2
206010053142 Olfacto genital dysplasia Diseases 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960003473 androstanolone Drugs 0.000 description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
230000037182 bone density Effects 0.000 description 2
210000001217 buttock Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
229940093499 ethyl acetate Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 2
201000003585 eunuchism Diseases 0.000 description 2
230000008713 feedback mechanism Effects 0.000 description 2
230000004907 flux Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
229940094892 gonadotropins Drugs 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
238000002513 implantation Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000007803 itching Effects 0.000 description 2
210000002332 leydig cell Anatomy 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
238000011474 orchiectomy Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000012286 potassium permanganate Substances 0.000 description 2
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000009256 replacement therapy Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 2
229960000746 testosterone undecanoate Drugs 0.000 description 2
150000003515 testosterones Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 1
DBPWSSGDRRHUNT-SJFWLOONSA-N (8r,9s,10r,13s,14s,17s)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-SJFWLOONSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
GAIHSQSRHYQICG-DACBVQKSSA-N 1-[(6s,8r,9s,10r,13s,14s,17r)-17-hydroxy-6,10,13-trimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@]12C)CCC=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 GAIHSQSRHYQICG-DACBVQKSSA-N 0.000 description 1
XAVRSHOUEXATJE-FBQZJRKBSA-N 1-[(8s,9s,10r,13s,14s,17s)-3-cyclopentyloxy-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)C(=O)C)C=C1C=C2OC1CCCC1 XAVRSHOUEXATJE-FBQZJRKBSA-N 0.000 description 1
CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 1
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QGXBDMJGAMFCBF-BNSUEQOYSA-N 3alpha-hydroxy-5beta-androstan-17-one Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@@H]21 QGXBDMJGAMFCBF-BNSUEQOYSA-N 0.000 description 1
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010003055 Application site reaction Diseases 0.000 description 1
102000014654 Aromatase Human genes 0.000 description 1
108010078554 Aromatase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
241000969130 Atthis Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
IVFYLRMMHVYGJH-VLOLGRDOSA-N Bolasterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-VLOLGRDOSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000283086 Equidae Species 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
XURCMZMFZXXQDJ-UKNJCJGYSA-N Gestonorone caproate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 XURCMZMFZXXQDJ-UKNJCJGYSA-N 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
208000018565 Hemochromatosis Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100023428 KH domain-containing, RNA-binding, signal transduction-associated protein 3 Human genes 0.000 description 1
208000008972 Laurence-Moon syndrome Diseases 0.000 description 1
201000004462 Leydig Cell Tumor Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029748 Noonan syndrome Diseases 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
RXXBBHGCAXVBES-XMUHMHRVSA-N Oranabol Chemical compound C1CC2=C(O)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 RXXBBHGCAXVBES-XMUHMHRVSA-N 0.000 description 1
QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
208000014993 Pituitary disease Diseases 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010043315 Testicular failure Diseases 0.000 description 1
206010043318 Testicular failure primary Diseases 0.000 description 1
208000022914 Testicular regression syndrome Diseases 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
206010062355 Unevaluable event Diseases 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
ODZDZTOROXGJAV-IRWJKHRASA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate Chemical compound C1CC(CCCC)CCC1C(=O)O[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 ODZDZTOROXGJAV-IRWJKHRASA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229950008564 anagestone Drugs 0.000 description 1
NSYTUNFHWYMMHU-IYRCEVNGSA-N androisoxazole Chemical compound C([C@@H]1CC2)C3=NOC=C3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 NSYTUNFHWYMMHU-IYRCEVNGSA-N 0.000 description 1
229950003633 androisoxazole Drugs 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229950008036 bolasterone Drugs 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003317 calciotropic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960001616 chlormadinone acetate Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
KCZCIYZKSLLNNH-FBPKJDBXSA-N clostebol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl KCZCIYZKSLLNNH-FBPKJDBXSA-N 0.000 description 1
229960001481 clostebol Drugs 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
229950006075 delmadinone acetate Drugs 0.000 description 1
CGBCCZZJVKUAMX-DFXBJWIESA-N delmadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 CGBCCZZJVKUAMX-DFXBJWIESA-N 0.000 description 1
229960001853 demegestone Drugs 0.000 description 1
JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940031578 diisopropyl adipate Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229950006690 dimethisterone Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
229960000445 ethisterone Drugs 0.000 description 1
XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
AOXRBFRFYPMWLR-XGXHKTLJSA-N ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 description 1
229960001460 ethylestrenol Drugs 0.000 description 1
229940012028 ethynodiol diacetate Drugs 0.000 description 1
229960000218 etynodiol Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
JKQQZJHNUVDHKP-SZMVRVGJSA-N flurogestone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@]2(F)[C@H]1[C@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@]1(C)C[C@@H]2O JKQQZJHNUVDHKP-SZMVRVGJSA-N 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
AMVODTGMYSRMNP-GNIMZFFESA-N formebolone Chemical compound C1CC2=CC(=O)C(C=O)=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@H]2O AMVODTGMYSRMNP-GNIMZFFESA-N 0.000 description 1
229950010292 formebolone Drugs 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229960005352 gestodene Drugs 0.000 description 1
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
229960003812 gestonorone caproate Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
229940068939 glyceryl monolaurate Drugs 0.000 description 1
208000002566 gonadal dysgenesis Diseases 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
229950002886 haloprogesterone Drugs 0.000 description 1
GCCIFDUTISMRTG-TUPTUZDRSA-N haloprogesterone Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C(=O)C)(Br)[C@@]2(C)CC1 GCCIFDUTISMRTG-TUPTUZDRSA-N 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
210000003100 hypothalamo-hypophyseal system Anatomy 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
210000004705 lumbosacral region Anatomy 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000037106 male hypogonadism Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229960000606 medrogestone Drugs 0.000 description 1
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004805 melengestrol Drugs 0.000 description 1
OKHAOBQKCCIRLO-IBVJIVQJSA-N melengestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)C)(O)[C@@]1(C)CC2 OKHAOBQKCCIRLO-IBVJIVQJSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229950008604 mestanolone Drugs 0.000 description 1
UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
229960005272 mesterolone Drugs 0.000 description 1
229960003377 metandienone Drugs 0.000 description 1
229960003578 metenolone Drugs 0.000 description 1
ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 description 1
229960000270 methylestrenolone Drugs 0.000 description 1
229960001566 methyltestosterone Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000008450 motivation Effects 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
229960004719 nandrolone Drugs 0.000 description 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
150000002826 nitrites Chemical class 0.000 description 1
ZDHCJEIGTNNEMY-XGXHKTLJSA-N norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 description 1
229960000492 norethandrolone Drugs 0.000 description 1
229940053934 norethindrone Drugs 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
229960001858 norethynodrel Drugs 0.000 description 1
229950011191 norgesterone Drugs 0.000 description 1
YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
229960000417 norgestimate Drugs 0.000 description 1
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
229960002831 norgestrienone Drugs 0.000 description 1
GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
238000010606 normalization Methods 0.000 description 1
VOJYZDFYEHKHAP-XGXHKTLJSA-N norvinisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C=C)[C@@H]4[C@@H]3CCC2=C1 VOJYZDFYEHKHAP-XGXHKTLJSA-N 0.000 description 1
229950004927 norvinisterone Drugs 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
GXHBCWCMYVTJOW-YGRHGMIBSA-N oxabolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O GXHBCWCMYVTJOW-YGRHGMIBSA-N 0.000 description 1
229950010171 oxabolone Drugs 0.000 description 1
229960000464 oxandrolone Drugs 0.000 description 1
229950008280 oxymesterone Drugs 0.000 description 1
229960005244 oxymetholone Drugs 0.000 description 1
ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
ZUBDXGHKAAMAAA-RFXJPFPRSA-N penmesterol Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)(O)C)C=C1C=C2OC1CCCC1 ZUBDXGHKAAMAAA-RFXJPFPRSA-N 0.000 description 1
RBFQPFFCDLXWQK-UXUCURBISA-N pentagestrone Chemical compound C([C@H]1[C@@H]2CC[C@]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)(O)C(=O)C)C=C1C=C2OC1CCCC1 RBFQPFFCDLXWQK-UXUCURBISA-N 0.000 description 1
229950009286 pentagestrone Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960002847 prasterone Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960001584 promegestone Drugs 0.000 description 1
QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229950000796 quingestrone Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000037390 scarring Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009182 swimming Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
230000002381 testicular Effects 0.000 description 1
229940010901 testosterone injection Drugs 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
MEHHPFQKXOUFFV-OWSLCNJRSA-N trenbolone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@H](CC3)O)C=C3)C3=C21 MEHHPFQKXOUFFV-OWSLCNJRSA-N 0.000 description 1
229960000312 trenbolone Drugs 0.000 description 1
229950003256 trengestone Drugs 0.000 description 1
USXVMPAWZOOYDE-HGUQNLGYSA-N trengestone Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 USXVMPAWZOOYDE-HGUQNLGYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Emergency Medicine (AREA)
Steroid Compounds (AREA)

OA1200300069A 2000-08-30 2001-08-29 Pharmaceutical composition and method for treatinghypogonadism. OA12386A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/651,777 US6503894B1 (en)	2000-08-30	2000-08-30	Pharmaceutical composition and method for treating hypogonadism

Publications (1)

Publication Number	Publication Date
OA12386A true OA12386A (en)	2006-04-17

Family

ID=24614189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300069A OA12386A (en)	2000-08-30	2001-08-29	Pharmaceutical composition and method for treatinghypogonadism.

Country Status (24)

Country	Link
US (13)	US6503894B1 (de)
EP (3)	EP2070517A3 (de)
KR (1)	KR100866715B1 (de)
CN (3)	CN1527714A (de)
AT (1)	ATE429920T1 (de)
AU (2)	AU2001290598B2 (de)
BR (1)	BRPI0113670B8 (de)
CY (1)	CY1110907T1 (de)
DE (1)	DE60138553D1 (de)
DK (1)	DK1313482T3 (de)
EA (1)	EA009815B1 (de)
ES (1)	ES2326621T3 (de)
HU (1)	HU230401B1 (de)
IL (2)	IL154668A0 (de)
MA (1)	MA27127A1 (de)
NO (1)	NO335506B1 (de)
NZ (1)	NZ524473A (de)
OA (1)	OA12386A (de)
PL (1)	PL205875B1 (de)
PT (1)	PT1313482E (de)
SI (1)	SI1313482T1 (de)
UA (1)	UA76958C2 (de)
WO (1)	WO2002017926A1 (de)
ZA (3)	ZA200301705B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN814496A0 (en) *	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
ID27922A (id) *	1998-06-11	2001-05-03	Endorech Inc	KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2418135C (en) *	2000-08-03	2011-09-20	Antares Pharma Ipl Ag	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) *	2000-08-03	2007-04-03	Antares Pharma Ipl Ag	Formulations for transdermal or transmucosal application
US20070225379A1 (en) *	2001-08-03	2007-09-27	Carrara Dario Norberto R	Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
US20040198706A1 (en) *	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
EP1347764B1 (de) *	2000-12-22	2007-03-14	Dr. August Wolff GmbH & Co. KG Arzneimittel	Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
ES2312593T3 (es)	2001-07-09	2009-03-01	Repros Therapeutics Inc.	Procedimientos y materiales para el tratamiento de la deficiencia de testosterona en hombres.
US7737185B2 (en) *	2001-07-09	2010-06-15	Repros Therapeutics Inc.	Methods and compositions with trans-clomiphene
PL370889A1 (en)	2001-12-20	2005-05-30	Femmepharma, Inc.	Vaginal delivery of drugs
AU2003228314C1 (en) *	2002-03-15	2009-03-26	Besins Healthcare Luxembourg Sarl	Androgen pharmaceutical composition and method for treating depression
TWI339122B (en) *	2002-03-15	2011-03-21	Lab Besins Iscovesco	Androgen pharmaceutical composition,kit containing the same and method for using the same
MY139721A (en) *	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
CA2489865C (en)	2002-06-25	2012-05-08	Acrux Dds Pty Ltd	Transdermal delivery rate control using amorphous pharmaceutical compositions
US20040115287A1 (en) *	2002-12-17	2004-06-17	Lipocine, Inc.	Hydrophobic active agent compositions and methods
EP1572171B1 (de) *	2002-12-18	2009-04-22	Laboratoires Besins International	Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
EP1572178B1 (de) *	2002-12-18	2006-05-03	Laboratoires Besins International	Behandlung von mastalgie mit4-hydroxy-tamoxifen
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (de)	2003-01-02	2009-04-22	Femmepharma Holding Co Inc	Pharmazeutische präparate für diebehandlung von erkrankungen und pathologischen zuständen der brust
NZ542499A (en) *	2003-04-01	2008-10-31	Besins Int Lab	Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7879357B2 (en) *	2003-04-28	2011-02-01	Bayer Schering Pharma Ag	Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JP4682129B2 (ja) *	2003-06-09	2011-05-11	アセンドセラピュティクスインコーポレイテッド	４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
US8883769B2 (en) *	2003-06-18	2014-11-11	White Mountain Pharma, Inc.	Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) *	2003-06-18	2004-12-23	White Hillary D.	Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20050042182A1 (en) *	2003-08-13	2005-02-24	Moshe Arkin	Topical compositions of urea
US20050037040A1 (en) *	2003-08-13	2005-02-17	Moshe Arkin	Topical compositions of urea and ammonium lactate
US20050036953A1 (en) *	2003-08-13	2005-02-17	Moshe Arkin	Topical compositions of ammonium lactate
US20050025833A1 (en) *	2003-07-16	2005-02-03	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) *	2003-07-16	2005-02-24	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) *	2003-07-16	2005-01-27	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
EP1670433B1 (de)	2003-10-10	2011-11-23	Antares Pharma IPL AG	Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
CA2549824C (en) *	2003-12-15	2012-03-13	Laboratoires Besins International	Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
EP1550440A1 (de) *	2003-12-15	2005-07-06	Laboratoires Besins International	Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie
US7968532B2 (en) *	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050143362A1 (en) *	2003-12-31	2005-06-30	Mclane Michael W.	Danazol for treatment of hypogonadism in the adult male
US20050271597A1 (en) *	2004-02-13	2005-12-08	Keith Alec D	Prostate hypertrophy treatment composition and method
US20050208139A1 (en) *	2004-03-22	2005-09-22	Ascend Therapeutics, Inc.	Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) *	2004-03-22	2009-03-24	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050244502A1 (en) *	2004-04-28	2005-11-03	Mathias Neil R	Composition for enhancing absorption of a drug and method
US7425340B2 (en) *	2004-05-07	2008-09-16	Antares Pharma Ipl Ag	Permeation enhancing compositions for anticholinergic agents
BRPI0513129A (pt) *	2004-07-14	2008-04-29	Repros Therapeutics Inc	método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
EP1634583A1 (de) *	2004-09-09	2006-03-15	Laboratoires Besins International	Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
US20090215906A1 (en) *	2005-02-04	2009-08-27	Repros Therapeutics Inc.	Methods and materials with trans-clomiphene for the treatment of male infertility
KR20070114187A (ko) *	2005-03-22	2007-11-29	레프로스 쎄라피우틱스 아이엔씨.	트랜스-클로미펜의 투약 방법
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
US20080058299A1 (en) *	2005-04-12	2008-03-06	Dudley Robert E	Method of treating or preventing bone deterioration or osteoporosis
EP1868590A4 (de) *	2005-04-13	2012-08-29	Unimed Pharmaceuticals Inc	Verfahren zur erhöhung der konzentration von testosteron und verwandten steroiden bei frauen
WO2007124250A2 (en)	2006-04-21	2007-11-01	Antares Pharma Ipl Ag	Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en)	2005-05-27	2011-11-29	Antares Pharma Ipl Ag	Method and apparatus for transdermal or transmucosal application of testosterone
KR20130114229A (ko) *	2005-06-03	2013-10-16	애크럭스 디디에스 피티와이 리미티드	경피 약물 전달 방법 및 조성물
US20070065494A1 (en) *	2005-08-03	2007-03-22	Watson Laboratories, Inc.	Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
DK2450041T3 (en)	2005-10-12	2018-11-19	Unimed Pharmaceuticals Llc	Enhanced testosterone gel for use in the treatment of hypogonadism
US7641675B2 (en) *	2006-03-08	2010-01-05	Warsaw Orthopedic, Inc.	Flexible bone plates and methods for dynamic spinal stabilization
TW200815045A (en) *	2006-06-29	2008-04-01	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of ropinirole and methods of use thereof
AU2007280440B2 (en) *	2006-07-31	2013-03-21	Besins Healthcare Luxembourg Sarl	Treatment and prevention of excessive scarring
EP1891945A1 (de) *	2006-07-31	2008-02-27	Laboratoires Besins International	Behandlung und Prävention von übermässiger Narbenbildung
US8206390B2 (en) *	2006-11-02	2012-06-26	Warsaw Orthopedic, Inc.	Uni-directional ratcheting bone plate assembly
WO2008067991A2 (en) *	2006-12-08	2008-06-12	Antares Pharma Ipl Ag	Skin-friendly drug complexes for transdermal administration
US20080153789A1 (en) *	2006-12-26	2008-06-26	Femmepharma Holding Company, Inc.	Topical administration of danazol
CA2674661C (en)	2007-01-11	2016-10-11	Acrux Dds Pty Ltd	Spreading implement
KR100871531B1 (ko) *	2007-01-16	2008-12-05	익수제약 주식회사	테스토스테론 외용제
US20080261937A1 (en) *	2007-03-23	2008-10-23	Dudley Robert E	Pharmaceutical compositions and method for treating pediatric hypogonadism
EA018775B1 (ru) *	2007-03-23	2013-10-30	Юнимед Фармасьютикалз Ллк	Применение тестостерона в форме водно-спиртового геля для лечения детского гипогонадизма
BRPI0818637A2 (pt)	2007-10-16	2015-04-07	Repros Therapeutics Inc	Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático
US8861813B2 (en) *	2008-03-13	2014-10-14	Mallinckrodt Llc	Multi-function, foot-activated controller for imaging system
US20110207765A1 (en) *	2008-10-31	2011-08-25	Moberg Derma Ab	Topical composition comprising a combination of at least two penetration enhancing agents
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20140288039A1 (en) *	2009-01-08	2014-09-25	Lipocine Inc.	Lipobalanced long chain testosterone prodrugs for oral delivery
US10080760B2 (en)	2009-10-27	2018-09-25	Besins Healthcare Luxembourg Sarl	Transdermal pharmaceutical compositions comprising active agents
AU2011329782A1 (en)	2010-11-18	2013-06-20	White Mountain Pharma, Inc.	Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en) *	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
JO3755B1 (ar) *	2011-01-26	2021-01-31	Ferring Bv	تركيبات تستوستيرون
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
KR20190117803A (ko) *	2011-05-15	2019-10-16	에이세러스 파마슈티칼즈 에스알엘	비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
UA113291C2 (xx)	2011-08-04	2017-01-10		Метаболіти транскломіфену і їх застосування
CA2889770A1 (en)	2012-11-02	2014-05-08	Repros Therapeutics Inc.	Trans-clomiphene for use in cancer therapy
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10201549B2 (en)	2013-06-14	2019-02-12	Professional Compounding Centers Of America (Pcca)	Testosterone combined with anastrozole injection solutions
USD750788S1 (en)	2013-11-26	2016-03-01	Acrux Dds Pty Ltd	Topical spreading applicator
USD749225S1 (en)	2013-11-26	2016-02-09	Acrux Dds Pty Ltd	Topical spreading applicator
US8785426B1 (en)	2013-12-13	2014-07-22	Upsher-Smith Laboratories, Inc.	Testosterone gel compositions and related methods
US11439668B2 (en)	2014-05-23	2022-09-13	JangoBio, LLC	Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) *	2014-05-23	2022-02-22	JangoBio, LLC	Methods to rebalance the hypothalamic-pituitary-gonadal axis
US20160051498A1 (en) *	2014-08-20	2016-02-25	Professional Compounding Centers Of America (Pcca)	Transdermal Pharmaceutical Compositions Including Testosterone and a C-SERM
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US20170014417A1 (en)	2015-07-14	2017-01-19	Lipp Life Sciences Llc	Pharmaceutical administration system for the transdermal application of vardenafil
US9824976B1 (en) *	2016-08-16	2017-11-21	Infineon Technologies Americas Corp.	Single-sided power device package
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
WO2019140087A1 (en)	2018-01-10	2019-07-18	Celista Pharmaceuticals Llc	Testosterone transdermal spray with film
ES3053765T3 (en)	2018-07-05	2026-01-26	Celista Pharmaceuticals Llc	Testosterone and estradiol transdermal spray
EP3824296A4 (de)	2018-07-20	2022-04-27	Lipocine Inc.	Lebererkrankung
US20250073246A1 (en) *	2023-08-29	2025-03-06	Shane Kelleher	Method of treating hypogonadism in men

Family Cites Families (369)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US568112A (en) *		1896-09-22		Vehicle-wheel
US2155658A (en)	1936-01-08	1939-04-25	Chemische Forschungs Gmbh	Surgical and medical preparations
NL109113C (de)	1957-03-27
US3121042A (en) *	1959-05-04	1964-02-11	Ercoli Alberto	Oral compositions containing 3-enolethers of methyltestosterone
GB916778A (en)	1959-10-15	1963-01-30	Vismara Francesco Spa	Oral compositions containing 3-substituted 17-ª--methyl testosterones
GB941634A (en)	1960-11-16	1963-11-13	Upjohn Co	Improvements in or relating to steroids and the manufacture thereof
US3218283A (en)	1962-07-26	1965-11-16	Monsanto Co	Novel solutions of poly-(acrylic anhydride) and poly-(methacrylic anhydride) polymers
US3164520A (en) *	1962-10-29	1965-01-05	Olin Mathieson	Injectable steroid compositions containing at least 75% benzyl benzoate
GB1158283A (en)	1965-10-21	1969-07-16	Foster Milburn Company	Composition to be Applied to Skin and Process for Preparing Same.
US3888995A (en)	1968-07-19	1975-06-10	Syntex Corp	Fatty alcohol-propylene glycol vehicle
US3887699A (en)	1969-03-24	1975-06-03	Seymour Yolles	Biodegradable polymeric article for dispensing drugs
US3913789A (en) *	1974-02-13	1975-10-21	United States Banknote Corp	Fluid container of the flexible wall capsule type
US4009254A (en)	1974-05-06	1977-02-22	Colgate-Palmolive Company	Topical compositions
US3939111A (en)	1974-07-01	1976-02-17	The B. F. Goodrich Company	Stable polyurethane solutions
US3989816A (en)	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4197316A (en) *	1975-07-23	1980-04-08	Scott Eugene J Van	Treatment of dry skin
NL7510104A (nl)	1975-08-27	1977-03-01	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US4078060A (en) *	1976-05-10	1978-03-07	Richardson-Merrell Inc.	Method of inducing an estrogenic response
CH625702A5 (de)	1977-01-18	1981-10-15	Delalande Sa
DE2747531A1 (de) *	1977-10-22	1979-04-26	Basf Ag	Substituierte 3-aminopyrazole
US4954487A (en)	1979-01-08	1990-09-04	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions
US4299826A (en)	1979-10-12	1981-11-10	The Procter & Gamble Company	Anti-acne composition
CA1165240A (en)	1980-07-09	1984-04-10	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions
US4346709A (en)	1980-11-10	1982-08-31	Alza Corporation	Drug delivery devices comprising erodible polymer and erosion rate modifier
US4442094A (en)	1980-12-23	1984-04-10	Merck & Co., Inc.	(3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US4440777A (en) *	1981-07-07	1984-04-03	Merck & Co., Inc.	Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4447562A (en)	1981-07-15	1984-05-08	Ivani Edward J	Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions
FR2515041A1 (fr)	1981-10-26	1983-04-29	Besins Jean	Medicament a base de progesterone pour le traitement des affections mammaires
FR2518879A1 (fr)	1981-12-30	1983-07-01	Besins Jean	Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
FR2519252A1 (fr)	1982-01-07	1983-07-08	Besins Jean	Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires
JPH0782147B2 (ja)	1982-10-21	1995-09-06	キヤノン株式会社	ズームレンズのフォーカシング方法
US4496556A (en)	1982-08-16	1985-01-29	Norman Orentreich	Topical applications for preventing dry skin
DE3315654A1 (de) *	1983-04-29	1984-10-31	Bosch Gmbh Robert	Polarographischer messfuehler fuer die bestimmung des sauerstoff-gehaltes in gasen
NL8301550A (nl)	1983-05-03	1984-12-03	Gist Brocades Nv	Imidazolethanol esters.
US4478822A (en)	1983-05-16	1984-10-23	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4557934A (en)	1983-06-21	1985-12-10	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4631188A (en)	1983-08-31	1986-12-23	S.K.Y. Polymers, Ltd. (Kingston Technologies)	Injectable physiologically-acceptable polymeric composition
DE3333240A1 (de)	1983-09-12	1985-03-28	Schering AG, 1000 Berlin und 4709 Bergkamen	Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4690775A (en)	1983-09-30	1987-09-01	Research Corporation	Emulsion-based gel and process for preparing same
DE3486448T2 (de)	1983-11-14	1997-10-09	Columbia Lab Inc	Bioadhäsive Mittel
US4670254A (en)	1983-12-09	1987-06-02	Toko Yakuhin Industry Co., Ltd.	Gel preparations for topical application of diclofenac sodium
FR2558373B1 (fr) *	1984-01-20	1987-07-03	Mauvais Jarvis Pierre	Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
GB8508404D0 (en)	1985-03-30	1985-05-09	Baylor College Medicine	Therapeutic compositions
CA1248450A (en)	1984-04-05	1989-01-10	Kazuo Kigasawa	Soft patch
GB8416234D0 (en)	1984-06-26	1984-08-01	Ici Plc	Biodegradable amphipathic copolymers
US4704282A (en)	1984-06-29	1987-11-03	Alza Corporation	Transdermal therapeutic system having improved delivery characteristics
US4725439A (en)	1984-06-29	1988-02-16	Alza Corporation	Transdermal drug delivery device
US4791099A (en)	1984-10-29	1988-12-13	Chaovanee Aroonsakul	Method of treatment for central nervous system diseases such as Alzheimer's's disease
GB2167408B (en)	1984-11-23	1988-05-25	Farmos Oy	Substituted imidazole derivatives and their preparation and use
EP0189861A3 (de)	1985-01-26	1988-02-17	Showa Denko Kabushiki Kaisha	Transdermaler Absorptionsbeschleuniger für ionische wasserlösliche Arzneistoffe
ATE77962T1 (de)	1985-02-25	1992-07-15	Univ Rutgers	Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US4663157A (en) *	1985-02-28	1987-05-05	The Proctor & Gamble Company	Sunscreen compositions
US4767627A (en)	1985-05-29	1988-08-30	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
JPS6211675U (de)	1985-07-04	1987-01-24
US4994265A (en)	1985-09-06	1991-02-19	Aloe Scientific Labs	Shaving composition
US4683242A (en)	1985-10-28	1987-07-28	A. H. Robins Company, Incorporated	Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
JPS62201819A (ja)	1985-11-13	1987-09-05	Res Dev Corp Of Japan	免疫不全症処置剤
DE3690626C2 (de)	1985-12-04	1997-05-15	Dean Hsieh	Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
US5731303A (en) *	1985-12-04	1998-03-24	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery compositions
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4699779A (en)	1986-02-18	1987-10-13	Victor Palinczar	Waterproof sunscreen compositions
US4820724A (en) *	1986-03-31	1989-04-11	University Of Southern California	Dual phase solvent carrier system
US4780320A (en)	1986-04-29	1988-10-25	Pharmetrix Corp.	Controlled release drug delivery system for the periodontal pocket
US4946870A (en)	1986-06-06	1990-08-07	Union Carbide Chemicals And Plastics Company Inc.	Delivery systems for pharmaceutical or therapeutic actives
US4863911A (en)	1986-08-04	1989-09-05	University Of Florida	Method for treating male sexual dysfunction
MY102980A (en)	1986-10-31	1993-03-31	Pfizer	Transdermal flux enhancing compositions
US4863970A (en)	1986-11-14	1989-09-05	Theratech, Inc.	Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4861764A (en) *	1986-11-17	1989-08-29	Macro Chem. Corp.	Percutaneous absorption enhancers, compositions containing same and method of use
US5326790A (en)	1986-11-19	1994-07-05	Dermatologic Research Corporation	Administration of skin medications by use of dicarboxylic acids and derivatives
AU601528B2 (en)	1986-12-22	1990-09-13	Ortho-Mcneil Pharmaceutical, Inc.	Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US4981696A (en)	1986-12-22	1991-01-01	E. I. Du Pont De Nemours And Company	Polylactide compositions
US4906169A (en) *	1986-12-29	1990-03-06	Rutgers, The State University Of New Jersey	Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en)	1987-02-26	1988-11-29	Alza Corporation	Transdermal administration of progesterone, estradiol esters, and mixtures thereof
BE1000381A4 (fr)	1987-03-13	1988-11-16	Pharlyse Sa	Preparation pharmaceutique a base d'indometacine.
US4855305A (en)	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
JPS6479103A (en)	1987-06-09	1989-03-24	Lion Corp	External preparation
US5013553A (en)	1987-06-30	1991-05-07	Vipont Pharmaceutical, Inc.	Drug delivery devices
US5256652A (en)	1987-11-12	1993-10-26	Pharmedic Co.	Topical compositions and methods for treatment of male impotence
JPH0798935B2 (ja)	1987-11-25	1995-10-25	有限会社野々川商事	品質劣化防止剤
US4920203A (en)	1987-12-17	1990-04-24	Allied-Signal Inc.	Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5223261A (en) *	1988-02-26	1993-06-29	Riker Laboratories, Inc.	Transdermal estradiol delivery system
US5719197A (en)	1988-03-04	1998-02-17	Noven Pharmaceuticals, Inc.	Compositions and methods for topical administration of pharmaceutically active agents
US5234957A (en)	1991-02-27	1993-08-10	Noven Pharmaceuticals, Inc.	Compositions and methods for topical administration of pharmaceutically active agents
US5446070A (en)	1991-02-27	1995-08-29	Nover Pharmaceuticals, Inc.	Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en)	1988-03-04	1997-08-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
IE62871B1 (en)	1988-03-08	1995-03-08	Warner Lambert Co	Compositions with enhanced penetration
US5231087A (en)	1988-03-16	1993-07-27	Cellegy Pharmaceuticals, Inc.	Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
US5641504A (en)	1988-06-09	1997-06-24	Alza Corporation	Skin permeation enhancer compositions using glycerol monolinoleate
EP0364211B1 (de)	1988-10-11	1994-12-21	Shire Holdings Ltd.	Arzneimittelpräparat für perkutane Absorption
EP0394429B1 (de) *	1988-10-27	1996-01-10	Schering Aktiengesellschaft	Mittel zur transdermalen applikation enthaltend gestoden
DE3836862A1 (de)	1988-10-27	1990-05-03	Schering Ag	Mittel zur transdermalen applikation von steroidhormonen
US5238944A (en) *	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5332577A (en)	1988-12-27	1994-07-26	Dermamed	Transdermal administration to humans and animals
CA2011423A1 (en)	1989-03-07	1990-09-07	Peter M. Taylor	Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
IL93693A (en) *	1989-03-10	2000-01-31	Endorech Inc	Pharmaceutical compositions for the treatment of estrogen sensitive diseases
US4917882A (en)	1989-03-16	1990-04-17	Amway Corporation	Gel-type sunscreen composition
US5053227A (en)	1989-03-22	1991-10-01	Cygnus Therapeutic Systems	Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5788983A (en)	1989-04-03	1998-08-04	Rutgers, The State University Of New Jersey	Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
ATE107517T1 (de)	1989-05-25	1994-07-15	Takeda Chemical Industries Ltd	Transdermales therapeutisches mittel.
US5059603A (en)	1989-06-12	1991-10-22	Centuries Laboratories, Inc.	Method and composition for treating impotence
US5122519A (en)	1989-06-27	1992-06-16	American Cyanamid Company	Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
ES2189784T3 (es)	1989-07-07	2003-07-16	Endorech Inc	Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
US5232703A (en) *	1989-07-21	1993-08-03	Izhak Blank	Estradiol compositions and methods for topical application
US5116828A (en) *	1989-10-26	1992-05-26	Nippon Zoki Pharmaceutical Co., Ltd.	Pharmaceutical composition for treatment of osteoporosis
US5324521A (en)	1989-12-18	1994-06-28	Dermamed	Systems for transdermal administration of medicaments
JP2893803B2 (ja)	1990-02-27	1999-05-24	日本電気株式会社	プラズマディスプレイの駆動方法
CA2083404C (en)	1990-06-01	2001-02-20	Alfred Moo-Young	Therapeutically effective topical application of st1435
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
MX9101787A (es)	1990-10-29	1992-06-05	Alza Corp	Formulaciones,metodos y dispositivos anticonceptivos transdermicos
WO1992007586A1 (en)	1990-10-31	1992-05-14	Beecham Group Plc	Topical composition with retinoid penetration enhancer
US5202125A (en)	1990-12-10	1993-04-13	Theratech, Inc.	Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5152997A (en)	1990-12-11	1992-10-06	Theratech, Inc.	Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
EP0491076A1 (de)	1990-12-19	1992-06-24	Theratech, Inc.	Penetrationsförderung mittels eines Mehrkomponentensystems aus N-aliphatischen Pyrrolidonen und niederen Alkoholen
JPH04261119A (ja)	1991-02-13	1992-09-17	Lintec Corp	経皮吸収型貼付剤
US5211952A (en)	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
US5340586A (en)	1991-04-12	1994-08-23	University Of Southern California	Methods and formulations for use in treating oophorectomized women
US5340585A (en)	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
TW218849B (de)	1991-05-17	1994-01-11	Bristol Myers Squibb Co
US5326566A (en)	1991-05-17	1994-07-05	Bristol-Myers Squibb Company	Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5208013A (en) *	1991-06-03	1993-05-04	Olympus International, Inc.	Composition for skin care and protection
US5252338A (en)	1991-06-27	1993-10-12	Alza Corporation	Therapy delayed
US5487898A (en) *	1991-08-26	1996-01-30	Abbott Laboratories	Compositions and method for the sublingual or buccal administration therapeutic agents
US5238933A (en)	1991-10-28	1993-08-24	Sri International	Skin permeation enhancer compositions
US5676968A (en)	1991-10-31	1997-10-14	Schering Aktiengesellschaft	Transdermal therapeutic systems with crystallization inhibitors
JP3202777B2 (ja)	1992-01-24	2001-08-27	リンテック株式会社	経皮吸収促進剤及びテープ製剤
US5629019A (en)	1992-02-27	1997-05-13	Alza Corporation	Formulations with hydrophobic permeation enhancers
TW224048B (de) *	1992-03-30	1994-05-21	Hoechst Roussel Pharma
JP2960832B2 (ja)	1992-05-08	1999-10-12	ペルマテックテクノロジーアクチェンゲゼルシャフト	エストラジオールの投与システム
US5605929A (en)	1992-05-27	1997-02-25	Arch Development Corp.	Methods and compositions for inhibiting 5α-reductase activity
WO1993025168A1 (en) *	1992-06-11	1993-12-23	Theratech, Inc.	The use of glycerin in moderating transdermal drug delivery
US5607691A (en) *	1992-06-12	1997-03-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
US5446025A (en)	1992-06-12	1995-08-29	Abbott Laboratories	Formulations and method of the percutaneous administration of leuprolide
EP0644764B1 (de)	1992-06-19	2000-05-17	The Regents of the University of California	Lipide zur epidermalen Befeuchtung und zur Wiederherstellung der Barrierefunktion
DE4223004A1 (de)	1992-07-13	1994-01-20	Liedtke Pharmed Gmbh	Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
ATE225646T1 (de)	1992-07-23	2002-10-15	Hisamitsu Pharmaceutical Co	Perkutan verabreichbare basiszusammensetzung und daraus hergestellte zusammensetzung
JP3276406B2 (ja)	1992-07-24	2002-04-22	富士通株式会社	プラズマディスプレイの駆動方法
CA2101496A1 (en)	1992-07-31	1994-02-01	Masao Kobayashi	Base for transdermal administration
DE4227989A1 (de)	1992-08-21	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
IL107328A0 (en)	1992-10-20	1994-01-25	Btg Pharma Corp	Composition for ameliorating muscle weakness/wasting in an hiv-1 infected patient
AU5449194A (en)	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
US5883115A (en)	1992-11-09	1999-03-16	Pharmetrix Division Technical Chemicals & Products, Inc.	Transdermal delivery of the eutomer of a chiral drug
US5639743A (en)	1992-11-13	1997-06-17	University Of Georgia Research Foundation	Compositions and methods for treating exocrine gland atrophy
WO1994013257A1 (en)	1992-12-16	1994-06-23	Creative Products Resource Associates, Ltd.	Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5776923A (en)	1993-01-19	1998-07-07	Endorecherche, Inc.	Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
IL108371A (en)	1993-01-19	2009-09-01	Endorech Inc	Use of sex steroid precursors to prepare medicaments for treatment of vaginal atrophy
US5881926A (en) *	1993-03-11	1999-03-16	Taro Pharmaceutical Industries, Ltd.	Pharmaceutical compositions in semisolid form and a device for administration thereof
US6010691A (en)	1993-03-19	2000-01-04	The Regents Of The University Of California	Methods for enhancing permeation of a topically administered physiologically active substance
IL109036A (en)	1993-03-19	1998-12-27	Cellegy Pharamaceuticals Inc	Preparations for detachment of the epithelial barrier function and use of means for the preparation of such preparations
IL109037A (en)	1993-03-19	1999-01-26	Cellegy Pharma Inc	Preparations for causing phase separation of lipid layers and preparation of the above preparations
DE69429768T2 (de) *	1993-04-05	2002-09-19	Competitive Technologies, Inc.	Diagnose und behandlung von erektilen funktionsstörungen
IT1271352B (it)	1993-04-08	1997-05-27	Boehringer Ingelheim Italia	Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CA2163003C (en) *	1993-05-19	2003-01-28	Akira Nakagawa	Solubilizer and external preparations containing the same
FR2705572B1 (fr)	1993-05-25	1995-08-11	Besins Iscovesco Laboratoires	Dihydrotestostérone pour androgénothérapie.
US5648350A (en)	1993-05-25	1997-07-15	Laboratoires Besins Iscovesco	Dihydrotestosterone for use in androgenotherapy
US5698589A (en) *	1993-06-01	1997-12-16	International Medical Innovations, Inc.	Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9311920D0 (en)	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
US5460820B1 (en)	1993-08-03	1999-08-03	Theratech Inc	Method for providing testosterone and optionally estrogen replacement therapy to women
US5362886A (en)	1993-10-12	1994-11-08	Eli Lilly And Company	Asymmetric synthesis
AU692504B2 (en)	1993-12-27	1998-06-11	Akzo Nobel N.V.	Percutaneously absorbable preparation
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
US6143746A (en)	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CN1106259A (zh)	1994-02-05	1995-08-09	日东制药株式会社	含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
FR2718372B1 (fr)	1994-04-08	1996-06-28	Sofab	Dispensateur de produits fluides.
ES2143049T3 (es)	1994-04-22	2000-05-01	Pentech Pharmaceuticals Inc	Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US6395744B1 (en)	1994-04-22	2002-05-28	Queen's University At Kingston	Method and compositions for the treatment or amelioration of female sexual dysfunction
US5540934A (en)	1994-06-22	1996-07-30	Touitou; Elka	Compositions for applying active substances to or through the skin
ATE194281T1 (de) *	1994-09-14	2000-07-15	Minnesota Mining & Mfg	Matrix für transdermale wirkstofffreisetzung
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
CN1170360A (zh)	1994-12-21	1998-01-14	瑟垃技术有限公司	具有粘性贴面和剥离密封圆片的经皮输送系统
US5807568A (en)	1994-12-27	1998-09-15	Mcneil-Ppc, Inc.	Enhanced delivery of topical compositions containing flurbiprofen
IL116539A (en)	1995-01-06	2002-02-10	Noven Pharma	Preparations given through the skin of unstable anti-acid drugs
US6024974A (en) *	1995-01-06	2000-02-15	Noven Pharmaceuticals, Inc.	Composition and methods for transdermal delivery of acid labile drugs
US5629021A (en)	1995-01-31	1997-05-13	Novavax, Inc.	Micellar nanoparticles
AT408067B (de) *	1995-03-17	2001-08-27	Gebro Pharma Gmbh	Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5654337A (en)	1995-03-24	1997-08-05	II William Scott Snyder	Topical formulation for local delivery of a pharmaceutically active agent
US5844103A (en)	1995-03-24	1998-12-01	Lever Brothers Company, Division Of Conopco, Inc.	Anionic glycasuccinamide sufactants and a process for their manufacture
FR2732223B1 (fr)	1995-03-30	1997-06-13	Sanofi Sa	Composition pharmaceutique pour administration transdermique
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
DE19517145C2 (de)	1995-05-10	2000-02-24	Hexal Pharmaforschung Gmbh	Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
AU5671496A (en)	1995-05-15	1996-11-29	Beth Israel Hospital	Use of dihydrotestosterone compounds for treating male sexual dysfunction
US5882676A (en) *	1995-05-26	1999-03-16	Alza Corporation	Skin permeation enhancer compositions using acyl lactylates
HU228434B1 (en)	1995-06-07	2013-03-28	Ortho Mcneil Pharm Inc	Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5785991A (en)	1995-06-07	1998-07-28	Alza Corporation	Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5693335A (en)	1995-06-07	1997-12-02	Cygnus, Inc.	Skin permeation enhancer composition for use with sex steroids
GB9512670D0 (en)	1995-06-21	1995-08-23	Sod Conseils Rech Applic	Camptothecin analogues
US5780050A (en)	1995-07-20	1998-07-14	Theratech, Inc.	Drug delivery compositions for improved stability of steroids
WO1997004752A1 (en)	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
US5906830A (en)	1995-09-08	1999-05-25	Cygnus, Inc.	Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en)	1995-09-14	1999-05-11	Cygnus, Inc.	Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US6036977A (en) *	1995-09-29	2000-03-14	L.A.M. Pharmaceutical Corp.	Drug preparations for treating sexual dysfunction
US6251436B1 (en)	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
JP4036496B2 (ja)	1995-10-24	2008-01-23	リンテック株式会社	ゲル製剤の製造方法
US5849729A (en)	1995-12-26	1998-12-15	Hershey Foods Corporation	Use of hydrolyzed cocoa butter for percutaneous absorption
AU1429697A (en)	1995-12-29	1997-07-28	Cygnus, Inc.	Systems and methods for the transdermal administration of androgenic agents
US5643587A (en)	1996-02-15	1997-07-01	Avon Products, Inc.	Composition and method for under-eye skin lightening
AUPN814496A0 (en) *	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
US6923983B2 (en)	1996-02-19	2005-08-02	Acrux Dds Pty Ltd	Transdermal delivery of hormones
US5898038A (en)	1996-03-19	1999-04-27	Board Of Regents, The University Of Texas System	Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5762956A (en)	1996-04-24	1998-06-09	Rutgers, The State University Of New Jersey	Transdermal contraceptive delivery system and process
AU2746397A (en)	1996-04-30	1997-11-19	Theratech, Inc.	Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
EP0952833A1 (de)	1996-05-02	1999-11-03	Azupharma GmbH	Topische penile androgen-applikation zur behandlung der erektilen dysfunktion
DE19619045C1 (de)	1996-05-02	1997-11-13	Jenapharm Gmbh	Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
IL127189A0 (en)	1996-05-22	1999-09-22	Diversified Pharmaceuticals In	Compositions methods and devices for the transdermal delivery of drugs
IT1283102B1 (it)	1996-06-06	1998-04-07	Permatec Nv	Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5730987A (en) *	1996-06-10	1998-03-24	Omar; Lotfy Ismail	Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5708038A (en)	1996-06-13	1998-01-13	Univera Pharmaceuticals, Inc.	Method of using aloe vera as a biological vehicle
US6007837A (en) *	1996-07-03	1999-12-28	Alza Corporation	Drug delivery devices and process of manufacture
US5770226A (en)	1996-07-10	1998-06-23	Wake Forest University	Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en)	1996-07-10	2000-10-31	Cedars-Sinai Medical Center	Combined pharmaceutical estrogen-androgen-progestin
RU2122396C1 (ru)	1996-07-12	1998-11-27	Валентина Александровна Андрюшина	Биологически-активная добавка в косметические изделия
US6228852B1 (en)	1996-07-12	2001-05-08	Carolyn V. Shaak	Transdermal application of naturally occurring steroid hormones
US5783208A (en)	1996-07-19	1998-07-21	Theratech, Inc.	Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5837289A (en)	1996-07-23	1998-11-17	Grasela; John C.	Transdermal delivery of medications using a combination of penetration enhancers
GB9616700D0 (en)	1996-08-09	1996-09-25	Carey Beverly J	Hormone supplement
AU4031897A (en)	1996-08-29	1998-03-19	Sekisui Kagaku Kogyo Kabushiki Kaisha	Stanozolol-containing percutaneously absorbable preparation
US5863560A (en) *	1996-09-11	1999-01-26	Virotex Corporation	Compositions and methods for topical application of therapeutic agents
JPH1087488A (ja)	1996-09-13	1998-04-07	Sekisui Chem Co Ltd	皮膚疾患治療用外用剤
US6225299B1 (en)	1996-09-16	2001-05-01	Jenapharm Gmbh & Co. Kg	Hormonal agent for skin treatment
US5760096A (en)	1996-10-18	1998-06-02	Thornfeldt; Carl R.	Potent penetration enhancers
CA2241188C (en)	1996-10-24	2007-07-31	Yeong Hua Huang	Hydrogel wound dressing and the method of making and using the same
US5952000A (en)	1996-10-30	1999-09-14	Theratech, Inc.	Fatty acid esters of lactic acid salts as permeation enhancers
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6019988A (en)	1996-11-18	2000-02-01	Bristol-Myers Squibb Company	Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
AU5374798A (en)	1996-12-05	1998-06-29	Bio-Technology General Corporation	Uses of oxandrolone
US5855920A (en) *	1996-12-13	1999-01-05	Chein; Edmund Y. M.	Total hormone replacement therapy
US5807957A (en)	1996-12-23	1998-09-15	Macrochem Corporation	Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6019997A (en)	1997-01-09	2000-02-01	Minnesota Mining And Manufacturing	Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
WO1998030198A1 (en)	1997-01-09	1998-07-16	Conrex Pharmaceutical Corporation	Composition for enhancing skin or hair
US5908619A (en)	1997-01-09	1999-06-01	Minnesota Mining And Manufacturing Company	Hydroalcoholic compositions thickened using surfactant/polymer complexes
DE19701949A1 (de)	1997-01-13	1998-07-16	Jenapharm Gmbh	Transdermales therapeutisches System
GB9700878D0 (en) *	1997-01-17	1997-03-05	Scherer Ltd R P	Dosage forms and method for ameliorating male erectile dysfunction
KR100215027B1 (ko)	1997-01-27	1999-08-16	성재갑	스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
US20010023261A1 (en)	1997-01-27	2001-09-20	Lg Chemical Limited.	Novel composition for the transdermal administration of drugs
CN1250373A (zh)	1997-02-07	2000-04-12	瑟垃技术有限公司	用于在具有睾酮缺乏症状的妇女中补充睾酮的组合物和方法
EP0979072B1 (de)	1997-02-28	2005-04-27	Minnesota Mining And Manufacturing Company	Transdermale vorrichtung zur verabreichungvon von testosteron
WO1998040076A1 (en)	1997-03-10	1998-09-17	Schering Aktiengesellschaft	Compositions for the treatment of climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with partial estrogen antagonists
US6416780B1 (en)	1997-05-07	2002-07-09	Galen (Chemicals) Limited	Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
GB2325855B (en)	1997-06-04	2001-08-29	Healthscene Ltd	Preparation for topical application to the male sexual organ
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
US20020012694A1 (en)	1997-09-17	2002-01-31	Alfred J. Moo-Young	Transdermal administration of ment
US6342250B1 (en) *	1997-09-25	2002-01-29	Gel-Del Technologies, Inc.	Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US5968919A (en)	1997-10-16	1999-10-19	Macrochem Corporation	Hormone replacement therapy drug formulations for topical application to the skin
US5877216A (en) *	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
US6037346A (en)	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2306837C (en)	1997-10-28	2007-05-08	Vivus, Inc.	Treatment of female sexual dysfunction
JP2003525845A (ja)	1997-10-28	2003-09-02	ヴィヴァス・インコーポレイテッド	勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
US6156753A (en)	1997-10-28	2000-12-05	Vivus, Inc.	Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en)	1997-10-28	2000-10-03	Vivus, Inc.	Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20020013304A1 (en) *	1997-10-28	2002-01-31	Wilson Leland F.	As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6472425B1 (en)	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
US6696484B2 (en)	1997-10-31	2004-02-24	University Of Chicago Office Of Technology And Intellectual Property	Method and compositions for regulation of 5-alpha reductase activity
US6046244A (en) *	1997-11-05	2000-04-04	Nexmed Holdings, Inc.	Topical compositions for prostaglandin E1 delivery
ATE418988T1 (de)	1997-11-10	2009-01-15	Strakan Int Ltd	Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
JP2004515446A (ja) *	1997-11-24	2004-05-27	ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド	テストステロン阻害剤及びニューロンの保護のためのその用途
GB9726916D0 (en)	1997-12-19	1998-02-18	Danbiosyst Uk	Nasal formulation
US6267984B1 (en)	1997-12-22	2001-07-31	Alza Corporation	Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US6054446A (en)	1997-12-24	2000-04-25	Sri International	Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO1999033458A1 (en)	1997-12-25	1999-07-08	Daiichi Pharmaceutical Co., Ltd.	Medicinal composition for percutaneous administration
US5935949A (en)	1998-03-20	1999-08-10	Trustees Of Dartmouth College	Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
EP2002839A1 (de) *	1998-04-17	2008-12-17	Ortho McNeil Pharmaceutical, Inc.	Folsäurehaltige pharmazeutische Zusammensetzungen und entsprechende Verfahren sowie Freisetzungssysteme
FR2777784B1 (fr)	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
US6124461A (en)	1998-05-26	2000-09-26	Saint Louis University, Health Services Center, Research Administration	Compounds, compositions, and methods for treating erectile dysfunction
US5847128A (en)	1998-05-29	1998-12-08	Virginia Commonwealth University	Water soluble derivatives of cannabinoids
US6277884B1 (en)	1998-06-01	2001-08-21	Nitromed, Inc.	Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6087368A (en)	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase
DE19825856A1 (de) *	1998-06-10	1999-12-16	Labtec Gmbh	Topische Arzneimittelzubereitung
US5942545A (en) *	1998-06-15	1999-08-24	Macrochem Corporation	Composition and method for treating penile erectile dysfunction
WO1999065563A1 (en)	1998-06-19	1999-12-23	Genetronics, Inc.	Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
EP1089736A2 (de)	1998-06-22	2001-04-11	Queen's University At Kingston	Methoden und zusammenstellungen zur behandlung von weiblicher sexueller dysfunktion
US6200591B1 (en) *	1998-06-25	2001-03-13	Anwar A. Hussain	Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE69927154T2 (de)	1998-06-25	2006-06-29	Lavipharm Laboratories, Inc.	Vorrichtung und verfahren zur behandlung von erektionsstörungen
MXPA00012844A (es)	1998-07-07	2004-05-21	Transdermal Technologies Inc	Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
US5880117A (en) *	1998-07-13	1999-03-09	Arnold; Patrick	Use of 4-androstenediol to increase testosterone levels in humans
US6207694B1 (en)	1998-07-27	2001-03-27	Howard Murad	Pharmaceutical compositions and methods for managing scalp conditions
US6284234B1 (en)	1998-08-04	2001-09-04	Johnson & Johnson Consumer Companies, Inc.	Topical delivery systems for active agents
US6436950B1 (en)	1998-08-14	2002-08-20	Nastech Pharmaceutical Company, Inc.	Nasal delivery of apomorphine
ATE264861T1 (de)	1998-09-04	2004-05-15	Ortho Mcneil Pharm Inc	5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
US6509005B1 (en)	1998-10-27	2003-01-21	Virginia Commonwealth University	Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6323242B1 (en)	1998-12-02	2001-11-27	Peter Sterling Mueller	Treatment of disorders secondary to organic impairments
EP1005831A3 (de)	1998-12-04	2001-05-30	Eisai Co., Ltd.	Penis Durchmesser Messmethode
WO2000040230A2 (en)	1999-01-06	2000-07-13	Cedars-Sinai Medical Center	Hormone replacement for breast cancer patients
US6224573B1 (en)	1999-01-15	2001-05-01	Nexmed Holdings, Inc.	Medicament dispenser
JP2000212080A (ja)	1999-01-26	2000-08-02	Hiroshi Azuma	勃起機能不全改善剤
US6117446A (en)	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
DE19903087A1 (de) *	1999-01-27	2000-08-10	Forssmann Wolf Georg	Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
RO121628B1 (ro)	1999-02-05	2008-01-30	Cipla Limited	Compoziţie medicinală, topică, pulverizabilă,dozator care o conţine, procedeu de realizare a dozatorului şi utilizarea compoziţiei menţionate
US6267985B1 (en)	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6087362A (en)	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
DE29907720U1 (de)	1999-04-30	1999-08-12	H. H. Heim und Haus Holding GmbH, 47169 Duisburg	Rolladenanordnung für horizontal zweigeteilte Fenster
WO2000067708A2 (en)	1999-05-07	2000-11-16	Board Of Regents, The University Of Texas System	Oral steroidal hormone compositions and methods of use
WO2000074684A1 (en)	1999-06-04	2000-12-14	The General Hospital Corporation	Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
CN1220491C (zh)	1999-06-11	2005-09-28	沃特森药物公司	非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
CA2379270C (en)	1999-07-16	2007-04-10	Nishizumi Nishimuta	External preparation for skin diseases containing nitroimidazole
US6187750B1 (en) *	1999-08-25	2001-02-13	Everyoung Technologies, Inc.	Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6075028A (en)	1999-09-23	2000-06-13	Graham; Richard	Method of treating Tourette's syndrome and related CNS disorders
US6980566B2 (en)	2000-03-10	2005-12-27	Lightwaves Systems, Inc.	Method for routing data packets using an IP address based in GEO position
US6582724B2 (en) *	1999-12-16	2003-06-24	Dermatrends, Inc.	Dual enhancer composition for topical and transdermal drug delivery
US6562370B2 (en)	1999-12-16	2003-05-13	Dermatrends, Inc.	Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
AU778475B2 (en)	1999-12-16	2004-12-09	Dermatrends, Inc.	Hydroxide-releasing agents as skin permeation enhancers
US6562369B2 (en)	1999-12-16	2003-05-13	Dermatrends, Inc.	Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6586000B2 (en)	1999-12-16	2003-07-01	Dermatrends, Inc.	Hydroxide-releasing agents as skin permeation enhancers
US6323241B1 (en)	2000-01-10	2001-11-27	Nexmed (Holdings) Inc.	Prostaglandin compositions and methods of treatment for male erectile dysfunction
WO2001052823A2 (en)	2000-01-20	2001-07-26	Noven Pharmaceuticals, Inc.	Compositions to effect the release profile in the transdermal administration of drugs
SK9592002A3 (en)	2000-01-28	2003-12-02	Endorech Inc	A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
EP1259204B1 (de)	2000-02-28	2007-04-18	Radiant Medical, Inc.	Wegwerfbare kassette für intravaskularen wärmetauschkatheter
DE10009423A1 (de)	2000-02-28	2001-09-06	Henkel Kgaa	Kosmetische und pharmazeutische Zubereitungen
WO2001072307A1 (en)	2000-03-29	2001-10-04	The J. David Gladstone Institutes	Methods of treating cognitive decline disease conditions with androgens
DE10015783C2 (de) *	2000-03-30	2003-12-04	Lohmann Therapie Syst Lts	Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
DE10019171A1 (de)	2000-04-07	2001-10-18	Schering Ag	Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
CN1471395A (zh) *	2000-04-07	2004-01-28	��ҽҩƷ��޹�˾	阿扑吗啡衍生物及其使用方法
CA2418135C (en) *	2000-08-03	2011-09-20	Antares Pharma Ipl Ag	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en)	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
CA2419573C (en) *	2000-08-30	2007-04-03	Unimed Pharmaceuticals, Inc.	Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
PT1315502E (pt)	2000-08-30	2010-05-06	Unimed Pharmaceuticals Llc	Método para tratar a disfunção eréctil e para aumentar a líbido em homens
JP5039252B2 (ja)	2000-08-31	2012-10-03	ユニメッドファーマシューティカルズ，リミティドライアビリティカンパニー	性機能低下を治療するための医薬組成物及び方法
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
US6743448B2 (en)	2000-12-11	2004-06-01	Abraham H. Kryger	Topical testosterone formulations and associated methods
EP1347764B1 (de) *	2000-12-22	2007-03-14	Dr. August Wolff GmbH & Co. KG Arzneimittel	Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
JP2002212105A (ja)	2001-01-22	2002-07-31	Lion Corp	水性皮膚外用剤組成物
WO2002092070A1 (en) *	2001-05-11	2002-11-21	Elan Corporation, Plc	Isostearic acid salts as permeation enhancers
US20030027804A1 (en)	2001-06-27	2003-02-06	Van Der Hoop Roland Gerritsen	Therapeutic combinations for the treatment of hormone deficiencies
US20030175329A1 (en)	2001-10-04	2003-09-18	Cellegy Pharmaceuticals, Inc.	Semisolid topical hormonal compositions and methods for treatment
US20040072810A1 (en) *	2001-11-07	2004-04-15	Besins International Belgique	Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
DK1317921T3 (da)	2001-12-07	2009-12-21	Besins Mfg Belgium	Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
AU2003212962A1 (en) *	2002-02-07	2003-09-02	Massachusetts Institute Of Technology	Transdermal drug delivery systems
TWI339122B (en) *	2002-03-15	2011-03-21	Lab Besins Iscovesco	Androgen pharmaceutical composition,kit containing the same and method for using the same
MY139721A (en)	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
CN1470239A (zh)	2002-07-28	2004-01-28	王怀秀	睾酮经皮缓释制剂
FR2848112B1 (fr) *	2002-12-10	2007-02-16	Besins Int Belgique	Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr)	2003-02-20	2007-11-16	Besins Int Belgique	Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20050020552A1 (en) *	2003-07-16	2005-01-27	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) *	2003-07-16	2005-02-24	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) *	2003-07-16	2005-02-03	Chaim Aschkenasy	Pharmaceutical composition and method for transdermal drug delivery
US7968532B2 (en)	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
US7138389B2 (en)	2004-02-09	2006-11-21	University Of Washington	Oral androgen therapy using modulators of testosterone bioavailability
US20050222106A1 (en)	2004-04-01	2005-10-06	Stefan Bracht	Drospirenone-containing preparations for transdermal use
RU2275930C2 (ru) *	2004-04-26	2006-05-10	ООО "РусГен"	Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции
US8907153B2 (en)	2004-06-07	2014-12-09	Nuvo Research Inc.	Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070190124A1 (en)	2004-06-07	2007-08-16	Jie Zhang	Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196323A1 (en)	2004-06-07	2007-08-23	Jie Zhang	Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20070196453A1 (en)	2004-06-07	2007-08-23	Jie Zhang	Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189977A1 (en)	2004-06-07	2007-08-16	Jie Zhang	Spray-on formulations and methods for dermal delivery of drugs
JP5244388B2 (ja)	2004-08-18	2013-07-24	ウオーターズ・テクノロジーズ・コーポレイシヨン	加圧下の流体を生成するかまたは運ぶための装置及び方法並びに該装置に用いられるシール部材
EP1634583A1 (de)	2004-09-09	2006-03-15	Laboratoires Besins International	Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
EP1647271A1 (de)	2004-10-14	2006-04-19	Laboratoires Besins International	Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
US20070082039A1 (en) *	2004-10-18	2007-04-12	Jones Gerald S Jr	Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
US20080058299A1 (en) *	2005-04-12	2008-03-06	Dudley Robert E	Method of treating or preventing bone deterioration or osteoporosis
EP1868590A4 (de) *	2005-04-13	2012-08-29	Unimed Pharmaceuticals Inc	Verfahren zur erhöhung der konzentration von testosteron und verwandten steroiden bei frauen
WO2006113227A2 (en)	2005-04-13	2006-10-26	Massachusetts Institute Of Technology	Compositions facilitating drug penetration and drug retention in skin
EP1871384A4 (de)	2005-04-15	2012-01-25	Clarus Therapeutics Inc	Systeme zur pharmazeutischen verabreichung hydrophober wirkstoffe und zusammensetzungen damit
KR20130114229A (ko)	2005-06-03	2013-10-16	애크럭스 디디에스 피티와이 리미티드	경피 약물 전달 방법 및 조성물
US20070065494A1 (en) *	2005-08-03	2007-03-22	Watson Laboratories, Inc.	Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
DE102005044008B4 (de) *	2005-09-14	2007-07-12	Krohne Ag	Verfahren zur Prüfung eines Massendurchflußmeßgeräts
DK2450041T3 (en) *	2005-10-12	2018-11-19	Unimed Pharmaceuticals Llc	Enhanced testosterone gel for use in the treatment of hypogonadism
US20070254036A1 (en)	2006-04-13	2007-11-01	Besins Healthcare Sa	Treatment of menopause associated symptoms
US20080220068A1 (en)	2006-07-31	2008-09-11	Laboratories Besins International	Treatment and prevention of excessive scarring
WO2008032718A1 (en)	2006-09-11	2008-03-20	Sekisui Chemical Co., Ltd.	Adhesive preparation
US20080261937A1 (en) *	2007-03-23	2008-10-23	Dudley Robert E	Pharmaceutical compositions and method for treating pediatric hypogonadism
ATE532016T1 (de) *	2008-07-23	2011-11-15	Telstar Technologies S L	Verfahren zur überwachung der zweiten trocknung in einem gefriertrocknungsverfahren

2000
- 2000-08-30 US US09/651,777 patent/US6503894B1/en not_active Expired - Lifetime
2001
- 2001-08-29 HU HU0302921A patent/HU230401B1/hu unknown
- 2001-08-29 DE DE60138553T patent/DE60138553D1/de not_active Expired - Lifetime
- 2001-08-29 PL PL366117A patent/PL205875B1/pl unknown
- 2001-08-29 BR BR0113670-4 patent/BRPI0113670B8/pt not_active IP Right Cessation
- 2001-08-29 OA OA1200300069A patent/OA12386A/en unknown
- 2001-08-29 SI SI200130925T patent/SI1313482T1/sl unknown
- 2001-08-29 CN CNA018171656A patent/CN1527714A/zh active Pending
- 2001-08-29 AT AT01970612T patent/ATE429920T1/de active
- 2001-08-29 WO PCT/US2001/027202 patent/WO2002017926A1/en not_active Ceased
- 2001-08-29 AU AU2001290598A patent/AU2001290598B2/en not_active Expired
- 2001-08-29 DK DK01970612T patent/DK1313482T3/da active
- 2001-08-29 EP EP09152484A patent/EP2070517A3/de not_active Ceased
- 2001-08-29 CN CN2007101092744A patent/CN101077350B/zh not_active Expired - Lifetime
- 2001-08-29 CN CN2006100066288A patent/CN101081203B/zh not_active Expired - Lifetime
- 2001-08-29 ZA ZA200301705A patent/ZA200301705B/en unknown
- 2001-08-29 KR KR1020037003029A patent/KR100866715B1/ko not_active Expired - Lifetime
- 2001-08-29 EP EP01970612A patent/EP1313482B1/de not_active Expired - Lifetime
- 2001-08-29 NZ NZ524473A patent/NZ524473A/en not_active IP Right Cessation
- 2001-08-29 AU AU9059801A patent/AU9059801A/xx active Pending
- 2001-08-29 EA EA200300313A patent/EA009815B1/ru not_active IP Right Cessation
- 2001-08-29 EP EP10179992.2A patent/EP2281553B1/de not_active Expired - Lifetime
- 2001-08-29 ES ES01970612T patent/ES2326621T3/es not_active Expired - Lifetime
- 2001-08-29 UA UA2003021832A patent/UA76958C2/uk unknown
- 2001-08-29 PT PT01970612T patent/PT1313482E/pt unknown
- 2001-08-29 IL IL15466801A patent/IL154668A0/xx active Protection Beyond IP Right Term
- 2001-10-19 US US10/046,454 patent/US20020183296A1/en not_active Abandoned
- 2001-10-19 US US10/033,101 patent/US20030050292A1/en not_active Abandoned
2003
- 2003-01-03 US US10/248,267 patent/US20030232072A1/en not_active Abandoned
- 2003-02-27 IL IL154668A patent/IL154668A/en active Protection Beyond IP Right Term
- 2003-02-27 MA MA27057A patent/MA27127A1/fr unknown
- 2003-02-28 ZA ZA200301687A patent/ZA200301687B/en unknown
- 2003-02-28 ZA ZA200301686A patent/ZA200301686B/en unknown
- 2003-02-28 NO NO20030961A patent/NO335506B1/no not_active IP Right Cessation
2004
- 2004-04-15 US US10/825,540 patent/US20050113353A1/en not_active Abandoned
- 2004-04-20 US US10/828,678 patent/US20050112181A1/en not_active Abandoned
- 2004-06-14 US US10/867,445 patent/US20050142173A1/en not_active Abandoned
2009
- 2009-07-27 CY CY20091100799T patent/CY1110907T1/el unknown
2011
- 2011-03-24 US US13/071,276 patent/US20110172196A1/en not_active Abandoned
- 2011-03-24 US US13/071,264 patent/US20110201586A1/en not_active Abandoned
2013
- 2013-05-24 US US13/902,035 patent/US20130261097A1/en not_active Abandoned
- 2013-07-15 US US13/942,245 patent/US9132089B2/en not_active Expired - Fee Related
- 2013-08-13 US US13/965,499 patent/US9125816B2/en not_active Expired - Fee Related
2015
- 2015-07-16 US US14/800,949 patent/US20150313914A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030232072A1 (en)	2003-12-18
ES2326621T3 (es)	2009-10-16
HUP0302921A2 (hu)	2004-01-28
NZ524473A (en)	2006-09-29
CN1527714A (zh)	2004-09-08
IL154668A0 (en)	2003-09-17
UA76958C2 (en)	2006-10-16
PL205875B1 (pl)	2010-06-30
CN101077350A (zh)	2007-11-28
US20050142173A1 (en)	2005-06-30
US20030050292A1 (en)	2003-03-13
KR20030064747A (ko)	2003-08-02
EP1313482B1 (de)	2009-04-29
PL366117A1 (en)	2005-01-24
US20110172196A1 (en)	2011-07-14
HUP0302921A3 (en)	2006-07-28
US9132089B2 (en)	2015-09-15
ZA200301705B (en)	2004-07-08
NO20030961D0 (no)	2003-02-28
US20050113353A1 (en)	2005-05-26
ATE429920T1 (de)	2009-05-15
DK1313482T3 (da)	2009-08-17
CY1110907T1 (el)	2015-06-10
BRPI0113670B1 (pt)	2018-02-14
US20110201586A1 (en)	2011-08-18
EP2281553B1 (de)	2020-12-02
AU9059801A (en)	2002-03-13
DE60138553D1 (de)	2009-06-10
US20050112181A1 (en)	2005-05-26
EA009815B1 (ru)	2008-04-28
EP1313482A1 (de)	2003-05-28
EP2281553A3 (de)	2012-11-14
EP2070517A3 (de)	2009-07-29
CN101081203A (zh)	2007-12-05
WO2002017926A1 (en)	2002-03-07
EP2070517A2 (de)	2009-06-17
BRPI0113670B8 (pt)	2021-05-25
US6503894B1 (en)	2003-01-07
NO335506B1 (no)	2014-12-22
CN101077350B (zh)	2012-06-27
CN101081203B (zh)	2010-09-29
US20140011788A1 (en)	2014-01-09
EA200300313A1 (ru)	2004-08-26
US9125816B2 (en)	2015-09-08
EP2281553A2 (de)	2011-02-09
US20020183296A1 (en)	2002-12-05
BR0113670A (pt)	2004-11-09
ZA200301687B (en)	2004-09-13
NO20030961L (no)	2003-04-25
AU2001290598B2 (en)	2006-07-13
KR100866715B1 (ko)	2008-11-03
MA27127A1 (fr)	2005-01-03
HU230401B1 (hu)	2016-04-28
PT1313482E (pt)	2009-07-29
US20130303501A1 (en)	2013-11-14
US20150313914A1 (en)	2015-11-05
ZA200301686B (en)	2004-04-19
US20130261097A1 (en)	2013-10-03
SI1313482T1 (sl)	2009-10-31
IL154668A (en)	2007-12-03